About Cell BioEngines
Cell BioEngines is a company based in Worcester (United States) founded in 2020 by Samuel Casey, Alexey Bersenev, Nathan Johnson, and Ajay Vishwakarma. Cell BioEngines has raised $2.53 million across 2 funding rounds from investors including New York State, SOSV and IndieBio. Cell BioEngines offers products and services including Stem Cell-based Platform and Allogeneic Cell Therapies. Cell BioEngines operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
- Headquarter Worcester, United States
- Founders Samuel Casey, Alexey Bersenev, Nathan Johnson, Ajay Vishwakarma
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cell Bioengines, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.53 M (USD)
in 2 rounds
-
Latest Funding Round
$2 M (USD), Seed
Jul 20, 2024
-
Investors
New York State
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cell BioEngines
Cell BioEngines offers a comprehensive portfolio of products and services, including Stem Cell-based Platform and Allogeneic Cell Therapies.
Platform for expanding and differentiating stem cells for clinical use.
Therapies targeting tumors using natural biology and off-the-shelf cells.
Funding Insights of Cell BioEngines
Cell BioEngines has successfully raised a total of $2.53M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cell BioEngines
Cell BioEngines has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include New York State, SOSV and IndieBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and accelerator services are provided across multiple sectors.
|
Locked | Locked | Locked | |
|
Biotech startups are accelerated through IndieBio's focused programs.
|
Locked | Locked | Locked | |
|
Provides the information about government agencies in New York
|
Locked | Locked | Locked |
Investor details for Cell BioEngines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cell BioEngines
Investment portfolio details for Cell BioEngines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cell BioEngines
Detailed financials for Cell BioEngines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cell Bioengines Comparisons
Peer comparison for Cell BioEngines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cell BioEngines
Cell BioEngines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of Cell BioEngines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cell Bioengines
Complete news archive for Cell BioEngines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cell BioEngines
Cell BioEngines was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Cell BioEngines is headquartered in Worcester, United States. It is registered at Worcester, Massachusetts, United States.
Ajay Vishwakarma is the current CEO of Cell BioEngines. They have also founded this company.
Cell BioEngines is a funded company, having raised a total of $2.53M across 2 funding rounds to date.
Founded in 2020 and based in Worcester, United States, cell therapies are developed by the company for oncology, tissue degeneration, and immune-related diseases. Proprietary live allogenic cell therapies are utilized, treating stem or immune cells as drugs. The BioEngine platform is employed, encompassing BioACCESS, BioANALYTICS, BioASSAYS, and BioMAN. Next-generation cell therapy companies are supported through the Cell BioVentures model. A drug candidate, MS-101, is advanced for SARS-related COVID-19 infections.
Cell BioEngines offers Stem Cell-based Platform and Allogeneic Cell Therapies.
Cell BioEngines has 3 investors. Key investors include New York State, SOSV, and IndieBio.